Quoin Receives FDA Clearance for Second Netherton Trial

FDA clears Quoin’s second QRX003 NS pivotal study - BioTuesdays

Quoin Pharmaceuticals (NASDAQ: QNRX) announced that the FDA has provided clearance to initiate a second Netherton Syndrome (NS) clinical pivotal study—CL-QRX003-002, for Quoin’s lead product QRX003. According to Quoin, clinical data from ongoing studies has demonstrated clear evidence of rapid, prolonged, and almost complete skin healing following a twice-daily application of QRX003 to the treatment areas, along with the almost complete eliminat…

Quoin Receives FDA Clearance for Second Netherton Trial

Quoin Pharmaceuticals advances QRX003 for Netherton Syndrome, receiving FDA clearance for a pivotal trial to assess its effectiveness and safety.